

Track record – Diseases – Interventions Adherence

Validation of the Adherence Barriers Questionnaire – an instrument for identifying potential risk factors associated with medication-related non-adherence. Müller S, Kohlmann T, Wilke T. *BMJ open. BMC Health Serv Res.* 2015 Apr 10;15:153. doi: 10.1186/s12913-015-0809-0.

Discontinuing Inappropriate Medication in Nursing Home Residents (DIM-NHR Study): protocol of a cluster randomised controlled trial. Wouters H, Quik EH, Boersma F, Nygård P, Bosman J, Böttger WM, Mulder H, Maring JG, Wijma-Vos L, Beerden T, van Doormaal J, Postma MJ, Zuidema SU, Taxis K. *BMJ open.* 2014 Oct 8;4(10):e006082. doi: 10.1136/bmjopen-2014-006082.

Medication monitoring and optimization: a targeted pharmacist program for effective and cost-effective improvement of chronic therapy adherence. van Boven JF, Stuurman-Bieze AG, Hiddink EG, Postma MJ, Vegter S. *J Manag Care Pharm.* 2014 Aug;20(8):786-92.

Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis. Vegter S, Oosterhof P, van Boven JF, Stuurman-Bieze AG, Hiddink EG, Postma MJ. *J Manag Care Pharm.* 2014 Jul;20(7):722-32.

Improving inhaler adherence in patients with chronic obstructive pulmonary disease: a cost-effectiveness analysis. van Boven JF, Tommelein E, Boussery K, Mehuys E, Vegter S, Brusselle GG, Rutten-van Mölken MP, Postma MJ. *Respir Res.* 2014 Jun 14;15:66. doi: 10.1186/1465-9921-15-66.

The effect of financial and educational incentives on rational prescribing. A state-space approach. Pechlivanoglou P, Wieringa JE, de Jager T, Postma MJ. *Health Econ.* 2014 Feb 11. doi: 10.1002/hec.3030. [Epub ahead of print]

Non-Adherence And Non-Persistence Related To Glp-1 Therapy In Patients With Diabetes Mellitus Type 2 (T2dm): Analysis of A Large German Claims-Based Dataset And Comparison To Oral Anti-Diabetics. Wilke T, Groth A, Berg B, Sikirica M, Martin AA, Fuchs A, Maywald U. *Value in Health.* 2014;17(7):A359.

Validation of the Adherence Barriers Questionnaire (ABQ) – An Instrument for Identifying Potential Risk Factors Associated with Medication-Related Non-Adherence. Müller S, Wilke T. *Value in Health.* 2014;17(7):A512.

Persistence with osteoporosis medication among newly-treated osteoporotic patients. van Boven JF, de Boer PT, Postma MJ, Vegter S. *J Bone Miner Metab.* 2013 Sep;31(5):562-70. doi: 10.1007/s00774-013-0440-2. Epub 2013 Apr 11.

How to use pharmacy claims data to measure patient nonadherence? The example of oral diabetics in therapy of type 2 diabetes mellitus. Wilke T, Groth A, Müller S, Reese D, Linder R, Ahrens S, Verheyen F. *Eur J Health Econ.* 2013;14(3):551-568.

Oral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Wilke T, Groth A, Müller S, Pfannkuche M, Verheyen F, Linder R, Maywald U, Kohlmann T, Feng YS, Breithardt G, Bauersachs R. *Thrombosis & Haemostasis.* 2012;107(6):1009–1194.

Compliance, persistence, and switching patterns for ACE inhibitors and ARBs. Vegter S, Nguyen NH, Visser ST, de Jong-van den Berg LT, Postma MJ, Boersma C. *Am J Manag Care.* 2011 Sep;17(9):609-16.

A novel approach for non-adherence measurement based on prescription data: the example of oral diabetics in the therapy of type-2 diabetes mellitus patients. Wilke T, Mueller S, Lindner R, Ahrens S, Verheyen F. *Value in Health.* 2011;14:A99.

Anforderungen an ein effektives Adherence-Persistence-Programm am Beispiel von oralen Antidiabetika bei Diabetes mellitus Typ 2-Patienten. Wilke T, Müller S, Groth A, Maywald U, Verheyen F. *Gesundheitsökonomie & Qualitätsmanagement.* 2011;16(5): 274-291.

Toward Identifying the Causes and Combinations of Causes Increasing the Risks of Nonadherence to Medical Regimens: Combined Results of Two German Self-Report Surveys. Wilke T, Müller S, Morisky D.E. *Value in Health.* 2011;14(8):1092–1100.

Does the package design matter? The influence of OTC package design on patients' drug knowledge. Wilke T, Müller S, Neumann K, Loder T. *Pharmaceutical Medicine*. 2011;25(5):307-317.

Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands. Pechlivanoglou P, Vehof J, van Agthoven M, de Jong-van den Berg LT, Postma MJ. *Clin Ther*. 2010 Jan;32(1):108-18. doi: 10.1016/j.clinthera.2010.01.00

The methodological quality and effectiveness of adherence interventions: a review of diabetes type II interventions. *Value in Health*. Wilke T, Müller S, Groth A 2010;13(7):A295–A296.

A conceptual framework that captures the multidimensional aspect of adherence in a health economic model: an application in chronic non-malignant pain management. Treur M, Houwing N, Heeg B, Kristanto P, Botteman M, Vo P, Marx S, Lockhart E, Van Hout B. *AD3. Value in Health* 01/2010; 13(7).

Non-Adherence in outpatient prophylaxis after major orthopedic surgery. Wilke T, Mook J, Müller S, Obert S, Pfannkuche M, Kurth A. 2010. *Clin Orthop Relat Res*. 2010;468(9):2437–2453.

Does the package design matter? The influence of OTC package design on patients' drug knowledge. Wilke T, Müller S, K. Neumann K, Loder T. *Value and Health*. 2010;13(7):A421.

The impact of medication switches induced by medication discount contracts on chronic patients' adherence. Groth A, Müller S, Wilke T. *Value in Health*. 2010;13(7):A360

Why do patients not adhere to prescribed medication regimes? Results of two German surveys. Wilke T, Müller S. *Value in Health*. 2010;13(7):A380.

Non-Adherence in outpatient prophylaxis after major orthopedic surgery. Wilke T. *Value in Health*. 2009;12(7):A221.

Predictors for starting depot administration of risperidone in chronic users of antipsychotics. Vehof J, Postma MJ, Bruggeman R, De Jong-Van Den Berg LT, Van Den Berg PB, Stolk RP, Burger H. *J Clin Psychopharmacol*. 2008 Dec;28(6):625-30. doi: 10.1097/JCP.0b013e31818a6d10.

Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands. Faber A, van Agthoven M, Kalverdijk LJ, Tobi H, de Jong-van den Berg LT, Annemans L, Postma MJ. *CNS Drugs*. 2008;22(2):157-70.

A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss. Treur M, Heeg B, Möller HJ, Schmeding A, van Hout B. *BMC Health Services Research* 03/2009; 9:32

A pharmaco-economic analysis of compliance gains on antipsychotic medications. Damen J, Thuresson PO, Heeg B, Lothgren M. *Applied Health Economics and Health Policy* 02/2008; 6(4):189-97

A pharmaco-economic analysis of schizophrenic patients switching from branded to generic risperidone involving a possible compliance loss. Treur M, Heeg B, Möller H, Schmeding A, van Hout BA. *PMH31 Value in Health* 01/2008; 11(3).

Adherence of pharmaco-economic studies to national guidelines in the Netherlands. Atthobari J, Bos JM, Boersma C, Brouwers JR, de Jong-van den Berg LT, Postma MJ. *Pharm World Sci*. 2005 Oct;27(5):364-70.

Switch patterns before and after patent expiry of omeprazole: a case study in The Netherlands. Klok RM, Boersma C, Oosterhuis I, Visser ST, de Jong-van den Berg LT, Postma MJ. *Aliment Pharmacol Ther*. 2006 Jun 1;23(11):1595-600.

Impact of pharmacist recommendations on the cost of drug therapy in ICU patients at a Malaysian hospital. Zaidi ST, Hassan Y, Postma MJ, Ng SH. *Pharm World Sci*. 2003 Dec;25(6):299-302.